Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261869 | PMC |
| http://dx.doi.org/10.1111/all.16571 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of major allergens Art v 1 and Art v 3 in pollen-induced asthma: a mouse model study.
Front Immunol
June 2025
International Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Background: pollen is a major airborne allergen contributing to seasonal allergic rhinitis and bronchial asthma worldwide. However, the specific allergenic potential of different species and their major allergens, Art v 1 and Art v 3, remains poorly understood.
Methods: This study utilized a BALB/c mouse model to comparatively assess the allergenic potential of , and Mice were sensitized and challenged with standardized pollen extracts, and allergic responses were evaluated through serum IgE levels, airway hyperreactivity, ear swelling, and histopathological lung analysis.
Pollen-induced asthma: a specific pheno-endotype of disease?
Eur Ann Allergy Clin Immunol
September 2025
Allergy Unit, Department of Internal Medicine, University Hospital delle Marche, Ancona, Italy.
Asthma is a heterogeneous syndrome with a significant social and economic impact. While the knowledge of pheno-endotypes has advanced in severe asthma, little attention has been paid to the phenotypes of mild-moderate asthma. Along this line, a systematic review of the current literature on pollen-induced asthma was carried out, targeting the question whether it can be considered a specific phenotype of disease, with a focus on the role of pollen and its interplay with asthma.
View Article and Find Full Text PDFFull consideration of the pollen exposure effect in clinical trial design for pollen-induced allergic rhinitis.
Expert Rev Clin Immunol
June 2025
Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Introduction: Allergic rhinitis (AR) is global health concern with an increasing prevalence. Among them, pollen-induced AR (PIAR) exhibits more severe and intense symptoms, decreased quality of life, prominent local inflammation, and is thus more challenging to control. Due to the difficulties in disease control, in recent years, an increasing number of treatment methods, including pharmacotherapy, allergen-specific immunotherapy, and newly developed biologics, have focused on PIAR.
View Article and Find Full Text PDFThe Severity of Pollen-Induced Allergic Rhinitis at 16 Years of Age: Data From the Population-Based BAMSE Birth Cohort.
Allergy
July 2025
Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Frederiksberg, Denmark.
Recent advances in the management of allergic rhinitis.
J Med Invest
April 2025
Laboratory of Pharmacology, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Allergic rhinitis (AR) is a type I allergic disease characterized by sneezing, watery rhinorrhea, and nasal obstruction. An epidemiological survey found that approximately 50% of Japanese individuals have AR.Histamine is a major chemical mediator that induces AR symptoms through its binding to histamine H1 receptor(H1R).
View Article and Find Full Text PDF